On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

FARGO, N.D. (Valley News Live) - Changes are coming to the way schizophrenia is treated. The US Food and Drug Administration ...

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in over 70 years. Schizophrenia affects nearly 3 million U.S. adults, but only ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates. Shares of the company were down 2.5% in extended trading.

(Reuters) -Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not achieve ...

A man has been charged with firearms and drugs offences after shotguns were found at a property in Coventry. West Midlands Police said the two weapons, one a sawn-off shotgun, were discovered ...

The dopamine hypothesis of schizophrenia is a scientific theory that suggests dopamine directly contributes to schizophrenia symptoms. Research on this theory and other causes of schizophrenia is ...